102 related articles for article (PubMed ID: 18559624)
1. MDM2 promoter polymorphism and pancreatic cancer risk and prognosis.
Asomaning K; Reid AE; Zhou W; Heist RS; Zhai R; Su L; Kwak EL; Blaszkowsky L; Zhu AX; Ryan DP; Christiani DC; Liu G
Clin Cancer Res; 2008 Jun; 14(12):4010-5. PubMed ID: 18559624
[TBL] [Abstract][Full Text] [Related]
2. MDM2 309T>G polymorphism and risk of lung cancer in a Korean population.
Park SH; Choi JE; Kim EJ; Jang JS; Han HS; Lee WK; Kang YM; Park JY
Lung Cancer; 2006 Oct; 54(1):19-24. PubMed ID: 16876289
[TBL] [Abstract][Full Text] [Related]
3. Prognostic potential of the MDM2 309T>G polymorphism in stage I lung adenocarcinoma.
Enokida Y; Shimizu K; Atsumi J; Kakegawa S; Takase Y; Kaira K; Yashima H; Araki T; Nakazawa S; Ohtaki Y; Nagashima T; Alexander L; Usui K; Ishikawa T; Hayashizaki Y; Takeyoshi I
Cancer Med; 2016 Aug; 5(8):1791-801. PubMed ID: 27228500
[TBL] [Abstract][Full Text] [Related]
4. Role of the MDM2 promoter polymorphism (-309T>G) in acute myeloid leukemia development.
Cingeetham A; Vuree S; Jiwatani S; Kagita S; Dunna NR; Meka PB; Gorre M; Annamaneni S; Digumarti R; Sinha S; Satti V
Asian Pac J Cancer Prev; 2015; 16(7):2707-12. PubMed ID: 25854351
[TBL] [Abstract][Full Text] [Related]
5. Impact of MDM2 polymorphism: increased risk of developing colorectal cancer and a poor prognosis in the Tunisian population.
Chaar I; Arfaoui TA; El Amine el HO; Mahmoud LB; Khiari M; Sammoud S; Lounis A; Amara S; Gharbi L; Hmida AB; Mzabi S; Bouraoui S
Eur J Gastroenterol Hepatol; 2012 Mar; 24(3):320-7. PubMed ID: 22266832
[TBL] [Abstract][Full Text] [Related]
6. Association between a functional single nucleotide polymorphism in the MDM2 gene and sporadic endometrial cancer risk.
Walsh CS; Miller CW; Karlan BY; Koeffler HP
Gynecol Oncol; 2007 Mar; 104(3):660-4. PubMed ID: 17123590
[TBL] [Abstract][Full Text] [Related]
7. Genetic polymorphisms of MDM2, cumulative cigarette smoking and nonsmall cell lung cancer risk.
Liu G; Wheatley-Price P; Zhou W; Park S; Heist RS; Asomaning K; Wain JC; Lynch TJ; Su L; Christiani DC
Int J Cancer; 2008 Feb; 122(4):915-8. PubMed ID: 17957785
[TBL] [Abstract][Full Text] [Related]
8. MDM2 polymorphism, survival, and histology in early-stage non-small-cell lung cancer.
Heist RS; Zhou W; Chirieac LR; Cogan-Drew T; Liu G; Su L; Neuberg D; Lynch TJ; Wain JC; Christiani DC
J Clin Oncol; 2007 Jun; 25(16):2243-7. PubMed ID: 17538168
[TBL] [Abstract][Full Text] [Related]
9. Association of MDM2 T309G and p53 Arg72Pro polymorphisms and gastroesophageal reflux disease with survival in esophageal adenocarcinoma.
Renouf DJ; Zhai R; Sun B; Xu W; Cheung WY; Heist RS; Kulke MH; Cescon D; Asomaning K; Marshall AL; Li S; Christiani DC; Liu G
J Gastroenterol Hepatol; 2013 Sep; 28(9):1482-8. PubMed ID: 23735059
[TBL] [Abstract][Full Text] [Related]
10. Association of Mouse Double Minute 2 -309T>G Polymorphism with Acute Myeloid Leukemia in an Iranian Population: A Case- Control Study.
Soleymannejad M; Sheikhha MH; Neamatzadeh H
Asian Pac J Cancer Prev; 2019 Oct; 20(10):3037-3041. PubMed ID: 31653152
[TBL] [Abstract][Full Text] [Related]
11. MDM2 promoter polymorphism is associated with both an increased susceptibility to gastric carcinoma and poor prognosis.
Ohmiya N; Taguchi A; Mabuchi N; Itoh A; Hirooka Y; Niwa Y; Goto H
J Clin Oncol; 2006 Sep; 24(27):4434-40. PubMed ID: 16983111
[TBL] [Abstract][Full Text] [Related]
12. Association of breast cancer outcome with status of p53 and MDM2 SNP309.
Boersma BJ; Howe TM; Goodman JE; Yfantis HG; Lee DH; Chanock SJ; Ambs S
J Natl Cancer Inst; 2006 Jul; 98(13):911-9. PubMed ID: 16818855
[TBL] [Abstract][Full Text] [Related]
13. MDM2 SNP309 polymorphism as risk factor for susceptibility and poor prognosis in renal cell carcinoma.
Hirata H; Hinoda Y; Kikuno N; Kawamoto K; Suehiro Y; Tanaka Y; Dahiya R
Clin Cancer Res; 2007 Jul; 13(14):4123-9. PubMed ID: 17634539
[TBL] [Abstract][Full Text] [Related]
14. MDM2 SNP309 associates with accelerated pancreatic adenocarcinoma formation.
Grochola LF; Müller TH; Bond GL; Taubert H; Udelnow A; Würl P
Pancreas; 2010 Jan; 39(1):76-80. PubMed ID: 19752772
[TBL] [Abstract][Full Text] [Related]
15. Elevated transcript levels from the MDM2 P1 promoter and low p53 transcript levels are associated with poor prognosis in human pancreatic ductal adenocarcinoma.
Grochola LF; Taubert H; Greither T; Bhanot U; Udelnow A; Würl P
Pancreas; 2011 Mar; 40(2):265-70. PubMed ID: 21404460
[TBL] [Abstract][Full Text] [Related]
16. Impact of TP53 codon 72 and MDM2 SNP 309 polymorphisms in pancreatic ductal adenocarcinoma.
Hori Y; Miyabe K; Yoshida M; Nakazawa T; Hayashi K; Naitoh I; Shimizu S; Kondo H; Nishi Y; Umemura S; Kato A; Ohara H; Inagaki H; Joh T
PLoS One; 2015; 10(3):e0118829. PubMed ID: 25734904
[TBL] [Abstract][Full Text] [Related]
17. MDM2 gene promoter polymorphisms and risk of lung cancer: a case-control analysis.
Li G; Zhai X; Zhang Z; Chamberlain RM; Spitz MR; Wei Q
Carcinogenesis; 2006 Oct; 27(10):2028-33. PubMed ID: 16675470
[TBL] [Abstract][Full Text] [Related]
18. MDM2 SNP309 is associated with poor outcome in B-cell chronic lymphocytic leukemia.
Gryshchenko I; Hofbauer S; Stoecher M; Daniel PT; Steurer M; Gaiger A; Eigenberger K; Greil R; Tinhofer I
J Clin Oncol; 2008 May; 26(14):2252-7. PubMed ID: 18467716
[TBL] [Abstract][Full Text] [Related]
19. Murine double minute clone 2,309T/G and 285G/C promoter single nucleotide polymorphism as a risk factor for breast cancer: a Polish experience.
Piotrowski P; Lianeri M; Rubis B; Knuła H; Rybczyńska M; Grodecka-Gazdecka S; Jagodziński PP
Int J Biol Markers; 2012 Jul; 27(2):e105-10. PubMed ID: 22467100
[TBL] [Abstract][Full Text] [Related]
20. Interaction of P53 Arg72Pro and MDM2 T309G polymorphisms and their associations with risk of gastric cardia cancer.
Yang M; Guo Y; Zhang X; Miao X; Tan W; Sun T; Zhao D; Yu D; Liu J; Lin D
Carcinogenesis; 2007 Sep; 28(9):1996-2001. PubMed ID: 17638920
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
